-+ 0.00%
-+ 0.00%
-+ 0.00%

Tasrif Pharmaceutical taps Abzena humanization, immunogenicity platforms for CD155 antibody program

PUBT·07/29/2026 22:56:22
Listen to the news
Tasrif Pharmaceutical taps Abzena humanization, immunogenicity platforms for CD155 antibody program
  • Tasrif Pharmaceutical expanded its collaboration with Abzena to develop a humanized anti-CD155 antibody program, led by TSRF-786C.
  • A second U.S. patent granted July 29, 2026 broadened protection for the antibody panel developed using Abzena’s humanization and immunogenicity platforms.
  • The lead candidate is being advanced toward IND-enabling safety and toxicology studies for systemic cancers, supported by non-human primate cross-reactivity.
  • Tasrif is also developing a CD155 x transferrin receptor bispecific for CNS delivery, following mouse glioblastoma proof-of-concept using a surrogate antibody.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abzena Ltd. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.